Agents for influenza neutralization

• US 9,683,030 B2
• Filed: 03/14/2013
• Issued: 06/20/2017
• Est. Priority Date: 05/10/2012
• Status: Active Grant

• Current Assignee: Massachusetts Institute of Technology
• Original Assignee: Massachusetts Institute of Technology
• Inventors: Raguram, S., Sasisekharan, Viswanathan, Soundararajan, Venkataramanan, Sasisekharan, Ram, Tharakaraman, Kannan, Subramanian, Vidya
• Primary Examiner(s): Boesen, Agnieszka
• Application Number:
  US13/829,675
• Publication Number:
  US 20130302348A1
• Time in Patent Office: 1,559 Days
• Field of Search: None
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 31/16 for influenza or rhinoviruses
• CPC Class Codes: C07K 16/1018 Orthomyxoviridae, e.g. influenza virus
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C07K 2317/92 Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
• CPC Class Codes: C07K 2317/94 Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

The present invention provides antibodies (e.g., monoclonal antibodies, human antibodies, humanized antibodies, etc.), which bind to multiple influenza strains. Such antibodies are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of influenza.

Claims

1. A composition comprising:

an engineered antibody that binds to an epitope in the membrane proximal epitope region (MPER) of hemagglutinin (HA), which antibody comprises a heavy chain having an amino acid sequence that is at least 95% identical to SEQ ID NO;

1 and a light chain having an amino acid sequence that is at least 95% identical to one of SEQ ID NO;

33-43.

2. The composition of claim 1, wherein the light chain includes at least CDR1 found in one of SEQ ID NO:

33-43.

3. The composition of claim 1, wherein the light chain includes at least CDR2 found in one of SEQ ID NO:

33-43.

4. The composition of claim 1, wherein the light chain includes at least CDR3 found in one of SEQ ID NO:

33-43.

5. The composition of claim 1, wherein the light chain includes each of CDR1, CDR2, and CDR3 found in one of SEQ ID NO:

33-43.

6. The composition of claim 1, wherein the light chain has the sequence set forth in one of SEQ ID NO:

33-43.

7. The composition of claim 1, wherein the light chain has a sequence that is at least 99% identical with one of SEQ ID NO:

33-43.

8. The composition of claim 1, wherein the heavy chain amino acid sequence includes at least one CDR that is identical to a CDR found in SEQ ID NO:

1.

9. The composition of claim 1, wherein the composition binds to at least two of HA polypeptides of subtype selected from the group of H1, H3, H5, H7, H9, and combinations thereof.

10. The composition of claim 1, wherein the engineered antibody is an IgG.

11. The composition of claim 1, wherein the engineered antibody is a monoclonal.

12. A cell line expressing the engineered antibody of claim 1.

13. The cell line of claim 12, wherein the cell line is a mammalian cell line.

14. The cell line of claim 12, wherein the cell line is a hybridoma.

15. The composition of claim 1, wherein the composition further comprises

a pharmaceutically acceptable excipient.

16. A kit comprising:

the composition of claim 1;

a syringe, needle, or applicator for administration of the at least one antibody to subject;

and instructions for use.